Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5515-5515
Author(s):  
Chunyan Lan ◽  
Yin Wang ◽  
Ying Xiong ◽  
Judong Li ◽  
Yanfang Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Oral Etoposide ◽  
Phase 2 ◽  
Open Label ◽  
Platinum Resistant ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Platinum Refractory ◽  
Vegfr Inhibitor

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document